局部进展期胃癌新辅助治疗的进展与争议

Progress and controversy of neoadjuvant therapy for locally advanced gastric cancer

胃癌是全世界常见的恶性肿瘤,我国仍是胃癌发病人数最多的国家,且多数病人确诊时已发展为局部进展期。传统根治性手术联合术后辅助治疗模式在改善病人预后方面陷入瓶颈期。近年来,化疗、放疗、靶向治疗及免疫治疗等新辅助治疗模式在局部进展期胃癌中的探索和应用不断取得进展。然而,有关新辅助治疗的获益人群、方案选择及疗效评估等方面尚未达成共识。笔者回溯国内外相关研究成果,深入分析局部进展期胃癌新辅助治疗的进展与争议。

Gastric cancer is one of the most common malignant tumors in the world.China is still the country with the highest incidence of gastric cancer and most patients with gastric cancer are in locally advanced stage at the first diagnosis.Traditional radical surgery combined with postoperative adjuvant treatment is difficult to further improve the prognosis of patients.In recent years,the exploration and application of neoadjuvant treatment modes such as chemotherapy,radiotherapy,targeted therapy and immunotherapy in locally advanced gastric cancer have made continuous progress.However,there is still no consensus on the benefit population,regimen options,and efficacy evaluation of neoadjuvant therapy.The authors review and comb the research progress and controversy of neoadjuvant therapy for locally advanced gastric cancer.